The first 1 million doses of smallpox vaccine were delivered to the Strategic National Stockpile (SNS), according to a U.S. Department of Health and Human Services (HHS) July 14 press release. The Danish manufacturer, Bavarian Nordic, is expected to deliver another 19 million doses sometime between now and 2013 as part of a BioShield contract administered by the Biomedical Advanced Research and Development Authority (BARDA), a part of the HHS Office of the Assistant Secretary for Preparedness and Response.
The modified Vaccinia Ankara (MVA) or Imvamune is intended for use in people who have weakened immune systems in the event of an emergency, such as a bioterrorism attack.
Bavarian Nordic, awarded the $505 million contract in 2007, is reportedly developing a freeze-dried version of Imvamune, which the company says may have an improved shelf life, reduce storage costs, and simplify transportation logistics.
In other news, the Assistant Secretary for Preparedness and Response announced July 13 a $54 million multiple year contract with Emergent BioDefense Operations Lansing (EBOL), for the domestic development of the anthrax vaccine in the company’s Lansing, Mich. facility. If product is licensed, according to a MedicalCountermeasures.gov press release, the manufacturing capacity for anthrax vaccine will increase multifold. Sources: HHS July 14 press release, Medical Counter Measures July 13 press release
We are looking for thought leaders to contribute content to AAPC’s Knowledge Center.
As a contributor you will produce quality content for the business of healthcare, taking the Knowledge Center forward with your knowhow and expertise. Earn CEUs and the respect of your peers.